A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1739 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 8 |
| 1740 | Th1178 | Elotuzumab | heavy chain EVQLVESG Full view | 689 | IIIc | Cancer | Empliciti | E.R. Squibb & Sons, L.L.C. | Powder Lyophilized for Solution | Intravenous | NA | SLAM family member 9 |
| 1753 | Th1181 | Filgrastim-sndz | NA Full view | 0 | IIIc | Cancer | Zarxio | Sandoz Inc | Solution | Intravenous; Subcutaneous | NA | NA |
| 1805 | Th1199 | Ramucirumab | ramucirumab|Homo sap Full view | 909 | IIIc | Cancer | Cyramza | Eli Lilly and Company | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Vascular endothelial growth factor receptor 2 |
| 1811 | Th1202 | Pembrolizumab | Heavy Chain Sequence Full view | 711 | IIIc | Cancer | Keytruda | Merck Sharp & Dohme Corp. | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1813 | Th1204 | Ofatumumab | Ofatumumab Heavy Cha Full view | 483 | IIIc | Cancer | Arzerra | Glaxo Smith Kline Llc | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | |
| 1815 | Th1206 | Nivolumab | Heavy Chain Sequence Full view | 710 | IIIc | Cancer | Opdivo | E.R. Squibb & Sons, L.L.C. | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1816 | Th1207 | Necitumumab | NA Full view | 0 | IIIc | Cancer | Portrazza | Eli Lilly and Company | Sterile, preservative free, clear to slightly opalescent and colorless to slightly yellow Solution | Intravenous | NA | NA |
| 1837 | Th1226 | Dinutuximab | NA Full view | 0 | IIIc | Cancer | unituxin | NA | sterile, preservative-free, clear/colorless to slightly opalescent solution | Intravenous | Antibody, Immunosuppresive agent, Antineoplastic agent | Ganglioside GD2 (small molecule) |
| 1843 | Th1231 | Ibritumomab tiuxetan | Heavy chain: QAYLQQS Full view | 652 | IIIc | Cancer | Zevalin | Spectrum Pharmaceuticals B.V. | Colourless Solution | Intravenous | Antibody, Immunosuppressive Agents | B-lymphocyte antigen CD20, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1848 | Th1236 | Sipuleucel-T | NA Full view | 0 | IIIc | Cancer | Provenge | NA | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Prostatic acid phosphatase |